Loading
9 standard-of-care settings across 4 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers | Age group | IDH |
|---|---|---|---|
| Screening, prevention and diagnosis | 1 | · | · |
| Advanced, first line | 1 | · | · |
| Second line | 1 | · | · |
| Other settings | 3 | 1 | 2 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Diagnosis | MRI with contrast; maximal safe resection with 5-ALA and intraoperative mapping, with early postoperative MRI to measure the extent of resection; integrated histo-molecular diagnosis with methylation classification where available. | 74 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Glioblastoma, newly diagnosed | Radiotherapy 60 Gy in 30 fractions with concurrent and 6 cycles adjuvant temozolomide; from age 65, short-course radiotherapy (40 Gy in 15 fractions) with temozolomide (CCTG CE.6); for older patients unfit for combined treatment, temozolomide alone or hypofractionated radiotherapy alone, chosen by MGMT status (Nordic, NOA-08); TTFields with maintenance temozolomide; trials for MGMT-unmethylated patients. | 94 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Glioblastoma, recurrent | Re-resection or LITT if feasible; lomustine; bevacizumab for oedema/steroid sparing; re-irradiation; clinical trial (CAR-T, FUS-BBB, vaccines) strongly preferred. | 76 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Glioblastoma | Resection → RT + temozolomide → TTFields; lomustine/bevacizumab at relapse. | NCCN Guidelines: Central Nervous System Cancers | 93 | |
| All comers | Oligodendroglioma grade 3 / astrocytoma grade 3 | Radiotherapy plus PCV (RTOG 9402, EORTC 26951) or temozolomide (CATNON). | 93 | ||
| All comers | H3 K27M diffuse midline glioma | Radiotherapy; dordaviprone at progression (2025); GD2 CAR-T and ONC201 first-line trials. | 61 | ||
| Age group | Paediatric low-grade glioma | Resection where safe; chemotherapy (carboplatin/vincristine) or tovorafenib / dabrafenib-trametinib for BRAF-altered relapsed disease; avoid radiation in young children. | 67 | ||
| IDH | IDH-mutant grade 2 | Resection → vorasidenib or observation; RT/PCV for high-risk. | NCCN Guidelines: Central Nervous System Cancers | 78 | |
| IDH | IDH-mutant grade 2 glioma | Maximal resection; vorasidenib for residual/recurrent disease (INDIGO); radiotherapy plus PCV or temozolomide for high-risk or progressive disease. | 78 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.